Equity Overview
Price & Market Data
Price: $25.21
Daily Change: +$1.31 / 5.20%
Range: $25.21 - $25.21
Market Cap: $2,080,891,648
Volume: 214
Performance Metrics
1 Week: 22.88%
1 Month: 25.99%
3 Months: 34.61%
6 Months: 34.61%
1 Year: 34.61%
YTD: 37.51%
Company Details
Employees: 567
Sector: Health technology
Industry: Pharmaceuticals: major
Country: China
Details
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.